Partnering and Collaborations
4SC is focused on developing small molecule drugs for the treatment of cancer. Through development partnerships with pharmaceutical and biotech companies as well as academia and clinics we aim to accelerate the development process and achieve market approval for our drug candidates and their availability to patients with cancer.
For our core drug candidates; resminostat, domatinostat and 4SC-208 we are open for partnering or collaborations with:
- Pharmaceutical companies to support further clinical development and/or to commercialize products after completing regulatory filings
- Investigators and clinical sites interested in performing investigator sponsored studies / research with our drug candidates either as monotherapy or in combination to improve existing therapies in cancer
- Biotech and Pharmaceutical companies to develop novel assets in synergy with our drug candidates
- Academia to support our pre-clinical efforts
If you are interested in collaborating with 4SC, please contact us.
Partners and licensees
In April 2011, 4SC AG granted Yakult Honsha Co., Ltd. (Yakult Honsha, Tokyo, Japan) an exclusive license for the development and marketing of resminostat in Japan. 4SC has received an upfront payment from Yakult Honsha and is eligible for milestone payments. In addition, Yakult Honsha will also be liable to pay 4SC double-digit royalties linked to product sales of resminostat.